Dr. Rong Fan, PhD is an Associate Professor of Biomedical Engineering at Yale University. Dr. Fan received his Ph.D. in chemistry from University of California at Berkeley. His graduate work involves the development of novel nanofluidic transistors for single molecule detection and ion transport control. Afterwards, he went on to take a postdoctoral associate position in Professor Jim Heath’s laboratory in NanoSystems Biology Cancer Center at CalTech. He is the recipient of numerous awards including the NSF Faculty Early Career Development, the Packard Fellowship for Science and Engineering, and the Bill & Melinda Gates Foundation GCE award and others. Dr. Fan's research focuses on combining single-cell analysis technology and systems biology to study cell-cell communication and cellular heterogeneity in human cancers and the immune system. Ultimately, the goal is to accelerate the translational development of these tools for informative immune monitoring or cancer diagnosis. Dr. Fan is the leader of the DFCI PS-OC Core.
Dr. Eric C. Holland, MD, PhD is the Principal Investigator (PI) of the PS-OC. Dr. Holland is the Director of the Alvord Brain Tumor Center; Chap and Eve Alvord and Elias Alvord Chair in Neuro-Oncology; and Professor in the Department of Neurological Surgery at the University of Washington and he is the Director of the Division of Human Biology and Solid Tumor Translational Research at the Fred Hutchinson Cancer Research Center in Seattle. He received his Ph.D. from the University of Chicago in 1985 and his MD from Stanford University in 1990. He is the recipient of numerous honorary degrees, awards and memberships in honorary societies and committees. Dr. Holland's research has centered on the development of genetically accurate mouse models of gliomas. He has used these models to study the biology of these tumors, the way they respond to current therapy, and the development of new therapeutic strategies for these tumors. Dr. Holland is the leader of Project 2.
Dr. Franziska Michor, PhD is the Principal Investigator (PI) of the Dana-Farber Cancer Institute Physical Science-Oncology Center (DFCI PS-OC). Dr. Michor is a Professor of Computational Biology in the Department of Biostatistics and Computational Biology at the Dana-Farber Cancer Institute, and in the Department of Biostatistics at the Harvard School of Public Health. Dr. Michor obtained her undergraduate in mathematics and molecular biology from the University of Vienna, Austria, and her PhD from the Department of Organismic and Evolutionary Biology at Harvard University. Afterwards, she was awarded a fellowship from the Harvard Society of Fellows, which she used to perform research at the Dana-Farber Cancer Institute. From 2007 until 2010, she was an Assistant Professor in the Computational Biology Program at Memorial Sloan-Kettering Cancer Center. Dr. Michor is the Principal Investigator of an NIH R01 and has been the recipient of multiple prizes including the Theodosius Dobzhansky Prize of the Society for the Study of Evolution, a Gerstner Young Investigator Award, a Leon Levy Young Investigator Award, the Vilcek Prize for Creative Promise in Biomedical Science and the Robertson Stem Cell Prize from the New York Stem Cell Foundation. Dr. Michor’s laboratory investigates the evolutionary dynamics of cancer initiation, progression, response to therapy, and emergence of resistance.
Dr. Kornelia Polyak, MD, PhD is a Professor of Medicine at Harvard Medical School and in the Department of Medical Oncology at the Dana-Farber Cancer Institute. Dr. Polyak is a physician-scientist involved in biomedical research directed towards patient care. Research in her laboratory is dedicated to the molecular analysis of human breast cancer. Her goal is to identify differences between normal and cancerous breast tissue, determine their consequences, and use this information to improve the clinical management of breast cancer patients. The lab have devoted much effort to develop new ways to study tumors as a whole and to apply interdisciplinary approaches. Using these methods Dr. Polyak has been at the forefront of studies analyzing purified cell populations from normal and neoplastic human breast tissue at genomic scale and in situ at single cell level and to apply mathematical and ecological models for the better understanding of breast tumor evolution. Her group has also been successful with the clinical translation of their findings including the testing of efficacy of JAK and BET bromodomain inhibitors for the treatment of triple negative and inflammatory breast cancer in Phase I/II clinical trials. Dr. Polyak has worked with Dr. Michor for the past 10 years and has successfully completed several high impact studies and successfully competed for grants. Dr. Polyak is the leader of Project 3.
Dr. David Scadden, MD is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He is a practicing hematologist/oncologist who focuses on bringing stem cell biology to patient care. He founded and directs the Center for Regenerative Medicine at the Massachusetts General Hospital and with Douglas Melton, co-founded and co-directs the Harvard Stem Cell Institute and the Harvard University Department of Stem Cell and Regenerative Biology. He is a member of the Institute of Medicine of the National Academies of Science, the Board of External Experts for the National Heart, Lung and Blood Institute and a former member of the National Cancer Institute’s Board of Scientific Counselors. Dr. Scadden received his MD from Case Western Reserve University School of Medicine. He has received multiple honorary degrees, awards and memberships in honorary societies. His work emphasizes targeting the stem cell niche to attain novel therapies for blood diseases. Dr. Scadden is the leader of Project 1